Lemborexant-induced interstitial lung disease: A case report.

Authors :: Nakahara S
Ishii Y
Egashira R
Tsubouchi K
Kohno M
Takenaka T
Tanaka K
Okamoto I
Source :: Respirology case reports [Respirol Case Rep] 2024 Apr 25; Vol. 12 (5), pp. e01334. Date of Electronic Publication: 2024 Apr 25 (Print Publication: 2024).
Publication Year :: 2024
Abstract: We report the first case of drug-induced interstitial lung disease attributed to lemborexant. A 66-year-old man reported to our hospital with the acute onset of cough and breathlessness with ground-glass opacity on radiological examination. Symptoms were identified after taking lemborexant for 2 consecutive days. The patient had undergone lemborexant treatment 2 years prior and had exhibited no symptoms at that time. The drug-induced lymphocyte stimulation test for lemborexant was positive. He showed rapid improvement upon treatment with steroid. With the rise in prescriptions of lemborexant for insomnia, lemborexant should be considered as a possible cause of drug-induced interstitial lung disease.<br />Competing Interests: Non declared.<br /> (© 2024 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.)